The independent source for health policy research, polling, and news.
661 - 680 of 690 Results
A proposal to change the way Medicare pays for some drugs has set off intense reaction and lobbying — all tied to a common theme: How far should the government go in setting prices for prescription drugs?
UnitedHealth’s OptumRx is the lowest bidder and wins a key endorsement ahead of final vote by California’s public retirement system.
The U.S. faces a variety of serious concerns beyond just the future of the federal health law.
In June, California will become the fifth state to allow terminally ill patients to end their lives with prescriptions from their doctors, but getting those prescriptions will require serious effort.
The analysis by Avalere examines changes in how silver plans on the insurance marketplaces handle coverage for high-cost specialty drugs.
How high-cost drugs are impacting California.
A study published in Health Affairs examines how physician-patient interactions often present missed opportunities to control patients’ health care spending.
An MIT economist and Harvard oncologist propose offering loans to patients to cover the cost of expensive, curative drugs, financed by private sector investment in loan securities.
Valeant Pharmaceuticals, the company that makes Seconal, the drug most commonly used in prescribed for terminally ill patients who want to end their lives, physician-assisted suicide, has doubled the price to more than $3,000.
More Medicare Part D drug plans are requiring coinsurance rather than copayments for more types of medications, making beneficiaries’ costs less predictable.
The proposal that Medicare made this month to better control prescription drug costs involves testing strategies used with some success in the private sector.
New Hampshire is expanding its website that lists the cost of specific medical procedures to include dental treatments and 65 prescription drugs. California is expanding its report cards on large medical groups to include cost of medical services by an average patient.
Regulators unveiled a two-part plan that will change payments and test ways in which the Medicare Part B program can change the incentives that some policy experts say encourage doctors to choose higher-cost medications.
There is more than one reason prices are rising, and no single solution.
The Centers for Medicare & Medicaid Services says access to special, lower-cost pharmacies has improved for Medicare beneficiaries in urban areas.
New hepatitis C drugs boast cure rates of at least 95 percent. But states are restricting their use for Medicaid patients and prisoners because the cost is so high.
In an analysis published Monday in JAMA Internal Medicine, researchers found that text message reminders help patients do better when it comes to taking their medicines. But questions about the specific ways to make the most of this strategy remain.
Heated battle expected over November ballot proposal to curb state’s prescription drug costs, as pharmaceutical industry opens its pocketbook to defeat the measure.
Experimental drugs might help desperate patients, but don’t count on an easy cure.
Some medicines, particularly intravenous treatments, are not listed in plans’ pharmacy benefit section and, therefore, it’s difficult to confirm coverage specifics.
© 2026 KFF